Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - ELITE PHARMACEUTICALS INC /NV/ | v217749_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
April 4, 2011
Date of Report (Date of earliest event reported)
ELITE PHARMACEUTICALS, INC.
(Exact name of Company as specified in its charter)
|
Delaware
|
001-15697
|
22-3542636
|
||
|
(State or other jurisdiction
|
(Commission
|
(IRS Employer
|
||
|
of incorporation)
|
File Number)
|
Identification No.)
|
165 Ludlow Avenue, Northvale, New Jersey 07647
(Address of principal executive offices)
(201) 750-2646
(Company’s telephone number, including area code)
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01
|
Other Events
|
On April 7, 2011, Elite Pharmaceuticals, Inc. (the “Company”) issued a press release to announce that the initial shipment of phentermine HCl 37.5 mg tablets was made to TAGI Pharma, a wholly owned subsidiary of Precision Dose, triggering a milestone payment under the License, Manufacturing and Supply Agreement.
A copy of the press release is being finished with this Current Report on Form 8-K as Exhibit 99.1, but is not incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
a) Not applicable.
b) Not applicable.
c) Not applicable.
d) Exhibits
|
Exhibit No.
|
Exhibit
|
|
|
99.1
|
Press Release dated April 7, 2011
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: April 7, 2011
|
ELITE PHARMACEUTICALS, INC.
|
||
|
By:
|
/s/ Chris Dick
|
|
|
Name:
|
Chris Dick
|
|
|
Title:
|
President and Chief Operating Officer | |